<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140004104A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140004104</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13756319</doc-number><date>20130131</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><priority-claims><priority-claim sequence="01" kind="regional"><country>EP</country><doc-number>07020120.7</doc-number><date>20071015</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>395</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>495</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>39558</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>495</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>4241331</main-classification><further-classification>4241731</further-classification></classification-national><invention-title id="d0e61">COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13424506</doc-number><date>20120320</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>13756319</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>13190752</doc-number><date>20110726</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>13424506</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12780640</doc-number><date>20100514</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>13190752</doc-number></document-id></child-doc></relation></continuation><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12234739</doc-number><date>20080922</date></document-id><parent-status>ABANDONED</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>12780640</doc-number></document-id></child-doc></relation></continuation></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>HOFFMANN-LA ROCHE INC.</last-name><address><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>FRIESS</last-name><first-name>THOMAS</first-name><address><city>DIESSEN-DETTENHOFEN</city><country>DE</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>KLEIN</last-name><first-name>CHRISTIAN</first-name><address><city>BONSTETTEN</city><country>CH</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>STREIN</last-name><first-name>PAMELA</first-name><address><city>WEINHEIM</city><country>DE</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>UMANA</last-name><first-name>PABLO</first-name><address><city>WOLLERAU</city><country>CH</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>HOFFMANN-LA ROCHE INC.</orgname><role>02</role><address><city>Nutley</city><state>NJ</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.</p></abstract></us-patent-application>